Syros Pharmaceuticals,Inc. (NASDAQ:SYRS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
(c) On September28, 2017, the Board of Directors (the “Board”) of Syros Pharmaceuticals,Inc. (the “Company”) appointed Nancy Simonian, M.D., the Company’s President and Chief Executive Officer, as the Company’s principal financial officer and Colleen DeSimone as the Company’s principal accounting officer.
Dr. Simonian, age 56, has served as the Company’s President and Chief Executive Officer since July2012. From 2001 to October2011, Dr.Simonian was employed by Takeda Pharmaceuticals Company, or Takeda, a publicly-held biopharmaceutical company, and at Millennium Pharmaceuticals,Inc., or Millennium, prior to its acquisition by Takeda, most recently serving as Chief Medical Officer and Senior Vice President of Clinical, Medical and Regulatory Affairs. From 1995 to 2001, Dr.Simonian served at Biogen,Inc., a publicly-held biotechnology company, most recently as Vice President of Clinical Development. She is a member of the boards of directors of Seattle Genetics,Inc., a biotechnology company, the Damon Runyon Cancer Research Foundation and the Biotechnology Industry Organization. Prior to joining the biopharmaceutical industry, Dr.Simonian was on the faculty of Massachusetts General Hospital and Harvard Medical School as an assistant professor of neurology. She received a B.A. in biology from Princeton University and an M.D. from the University of Pennsylvania School of Medicine.
Ms.DeSimone, age 47, has served as the Company’s Vice President of Finance since April2015. From 1997 to December2014, Ms.DeSimone served in a number of progressively responsible positions in the finance group at Takeda, at Millennium prior to its acquisition by Takeda, and at LeukoSite,Inc. prior to its acquisition by Millennium, most recently as Senior Director, Finance and Controller of Takeda Oncology. Previously, Ms.DeSimone was a senior accountant at Deloitte& Touche LLP. Ms.DeSimone earned a B.A. in economics and accounting from the College of the Holy Cross and is a certified public accountant in the Commonwealth of Massachusetts.
Our certificate of incorporation provides for the Company to indemnify its directors and executive officers to the fullest extent permitted by Delaware law. On September28, 2017, we entered into an indemnification agreement with Ms.DeSimone on terms identical to those entered into with the Company’s other directors and executive officers. This indemnification agreement requires the Company, among other things, to advance expenses, including attorneys’ fees, to our directors and executive officers in connection with an indemnification claim, subject to very limited exceptions.
Item 9.01 Financial Statements and Exhibits.